---
schema_version: "secwatch.filing_event.v1"
accession: "0001434647-26-000041"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2026-06-05T20:19:10+00:00"
generated_at: "2026-06-05T20:31:42.090425+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Zevra shareholders elect directors, ratify auditor; board declassification fails

## Summary
- Douglas W. Calder elected as Class II director with 25.8M for, 8.0M withheld (12.6M broker non-votes).
- Corey Watton elected as Class II director with 29.9M for, 3.8M withheld (12.6M broker non-votes).
- Ratification of Ernst & Young as auditor for FY 2026 approved: 45.9M for, 234.8K against, 144.6K abstain.
- Proposal to declassify board failed; received 32.6M for vs. 1.1M against, needed >66-2/3% of outstanding shares.

## SEC filing metadata
- accession: 0001434647-26-000041
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2026-06-05T20:19:10+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143464726000041/0001434647-26-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143464726000041/zvra-20260604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001434647-26-000041
- JSON: https://secwatch.observer/filing/0001434647-26-000041.json
- Plain text: https://secwatch.observer/filing/0001434647-26-000041.txt

## Key facts
- Shareholder Votes
  ZEVRA THERAPEUTICS, INC. shareholders approved Election of Class II Directors at the 2026-06-04 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: At the 2026 Annual Meeting of Stockholders of Zevra Therapeutics, Inc. (the “Company”) held on June 4, 2026 (the “Annual Meeting”), the stockholders of the Company voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 20, 2026 (File No. 001-36913) (the “Proxy Statement”): (1) to elect Douglas W. Calder and Corey Watton to the Company’s Board as Class II directors to hold office until the 2029 annual meeting of stockholders, and until their respective successors shall have been duly elected and qualified (“Proposal 1”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143464726000041/0001434647-26-000041-index.htm
- Shareholder Votes
  ZEVRA THERAPEUTICS, INC. shareholders approved Ratification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: Proposal 2 — Ratification of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm: For Against Abstain Broker Non-Votes 45,947,281 234,753 144,582 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143464726000041/0001434647-26-000041-index.htm
- Shareholder Votes
  ZEVRA THERAPEUTICS, INC. shareholders rejected Approve an amendment to the Restated Certificate of Incorporation to phase out the classified Board structure and provide that all directors elected at or after the 2027 annual meeting be elected on an annual basis at the 2026-06-04 meeting.
  - Proposal: charter amendment
  - Outcome: failed
  - Meeting: 2026-06-04
  source text: Proposal 3 — Vote to Approve an Amendment to the Charter to Declassify the Board: For Against Abstain Broker Non-Votes 32,557,653 1,145,079 16,950 12,606,934
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143464726000041/0001434647-26-000041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.